title: Biomedicine. Rare cancer successes spawn 'exceptional' research efforts.
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Kaiser
mesh_terms: D017766:Acid Anhydride Hydrolases; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological; D035843:Biomedical Research; D017321:Clinical Trials, Phase I as Topic; D045643:DNA Repair Enzymes / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D000068338:Everolimus; D005260:Female; D006801:Humans; D054547:National Cancer Institute (U.S.); D012074:Remission Induction; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics; D014481:United States; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D004268:DNA-Binding Proteins; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins; D000068338:Everolimus; D017766:Acid Anhydride Hydrolases; C112158:RAD50 protein, human; D045643:DNA Repair Enzymes; D020123:Sirolimus